Eligo Bioscience

Scientists have designed a gene-editing tool that can modify bacterial populations in the gut microbiome of living mice go.nature.com/3S3y5QJ

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠: 𝐄𝐥𝐢𝐠𝐨 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐅𝐢𝐫𝐬𝐭-𝐄𝐯𝐞𝐫 𝐢𝐧 𝐕𝐢𝐯𝐨 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐁𝐚𝐬𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 In an article published moments ago in Nature, the company demonstrates for the first time ever that it is possible to target a bacterial genome with extreme precision and efficiency in the gut of a living mouse. Speaking with CRISPR Medicine News, Eligo Bioscience' CEO Xavier Duportet said: »It's really the first time we can envision creating therapies that can precisely inactivate the bacterial gene(s) driving disease while having close to no impact on microbiome composition and function. This could be a paradigm shift, switching from microbiome therapies to gene-editing therapies targeting bacterial genes - this strategy broadens the landscape of addressable therapeutic targets in the gene-editing field«. Read more 👇🏻 crisprmedicinenews.com/news/breaking-… Photo L-R: Jesus Fernandez-Rodriguez, PhD (VP of Technology, Eligo Bioscience), Xavier Duportet (Co-founder and CEO, Eligo Bioscience), David Bikard (Co-founder, Eligo Bioscience and Professor in Synthetic Biology at Institut Pasteur, France). #crisprmedicinenews #crisprmedicine #crispr #baseediting #microbiome #breakingnews #researchbreakthrough

#News: We are proud to announce a partnership worth up to $224M with @GSK to develop a CRISPR-based microbiome therapy for the millions of patients suffering of acne every year. eligo.bio #Microbiome #Inflammation #Acne #Crispr